Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Abstract
OBJECTIVES: To evaluate varenicline's efficacy for smoking cessation versus bupropion SR and placebo and to explore whether factors typically predictive of abstinence influence varenicline's efficacy versus placebo, as measured by the week 9-12 continuous abstinence rate (CAR9-12). METHODS: Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n=696), bupropion SR 150 mg BID (n=671), or placebo (n=685) for 12 weeks. Nontreatment followup lasted 40 weeks. RESULTS: CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P<0.0001) and placebo (17.7%; P<0.0001). CAR(9-12) for varenicline versus placebo was not affected by age, gender, or nicotine dependence level. CONCLUSIONS: Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Varenicline increases continuous abstinence rates to approximately 50% following 12 weeks of treatment, significantly better than bupropion (approximately 30%) or placebo (approximately 18%).
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Nides et al., 2008
Cited by
Sorted by citations
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747 · see citing works
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433 · see citing works
Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162 · see citing works
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138 · see citing works
Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136 · see citing works
Chang, P.-H., Chiang, C.-H., Ho, W.-C., Wu, P.-Z., Tsai, J.-S., & Guo, F.-R. (2015) · BMC Public Health · doi:10.1186/s12889-015-2055-0 · Cited by 108 · see citing works
Turner, J. R., Castellano, L. M., & Blendy, J. A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166280 · Cited by 88 · see citing works
Turner, J. R., Castellano, L. M., & Blendy, J. A. (2011) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq206 · Cited by 78 · see citing works
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46 · see citing works
Gonzales, D., Jorenby, D. E., Brandon, T. H., Arteaga, C., & Lee, T. C. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03058.x · Cited by 37 · see citing works
- Authors
- Nides, M.
- Corresponding author
- Nides, Mitchell
- Venue
- American Journal of Health Behavior
- Publisher
- JCFCorp SG PTE LTD
- Published
- 2008
- Volume
- 32
- Issue
- 6
- Pages
- 664-75
- ISSN
- 1087-3244 (ISSN-L)
- OpenAlex
- W4250204111
- Cited by
- 121
- References
- 0
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 6 · 2015: 14 · 2014: 4 · 2013: 9 · 2012: 10
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health Behavior (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- varenicline, bupropion, smoking cessation, nicotine replacement therapy, nicotinic antagonists, pooled analysis, placebo comparison
- MeSH terms
- Varenicline, Smoking Prevention, Adolescent, Adult, Aged, Benzazepines, Double-Blind Method, Follow-Up Studies, Humans, Middle Aged, Quinoxalines, Smoking, Smoking Cessation, Bupropion, Antidepressive Agents, Second-Generation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
